Organization · Private Equity
JEITO
Jeito Capital is a private equity firm based in Paris that focuses on financing and accelerating medical innovations in the biopharmaceutical sector. The firm operates primarily in Europe and the United States.
Overview
What JEITO does
What JEITO is
Jeito Capital is a private equity firm based in Paris that focuses on financing and accelerating medical innovations in the biopharmaceutical sector. The firm operates primarily in Europe and the United States.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- March 4, 2026
Official channels
Find JEITO elsewhere
Open the official website or a supported primary organization account.
Capability profile
JEITO as a funder
Investment thesis
Jeito Capital invests in biopharmaceuticals and innovative medical companies, particularly in therapeutic areas such as immuno-oncology and cardiology. The organization supports companies from clinical trials to market access.
Focus narrative
Jeito Capital invests in biopharmaceuticals and innovative medical companies, focusing on therapeutic areas such as immuno-oncology, ophthalmology, cardiology, severe respiratory diseases, and fibrosis. The organization supports companies at various stages of development, from clinical trials to market access, primarily in Europe and the United States.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B · Series C
- Regions
- EuropeUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Neogene Therapeutics
Portfolio context
Jeito Capital's portfolio includes notable companies such as Neogene Therapeutics, acquired by AstraZeneca in January 2023, and SparingVision, which develops gene therapies for retinal degeneration. Other portfolio companies include Pulmocide, Alentis Therapeutics, Quell Therapeutics, and NMD Pharma, each focusing on innovative treatments in the biopharma sector.
Common questions
What to know about JEITO
Upseed classifies JEITO under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 4, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.